Vemurafenib enhances MHC induction in BRAF(V600E) homozygous melanoma cells
about
The evolution of combined molecular targeted therapies to advance the therapeutic efficacy in melanoma: a highlight of vemurafenib and cobimetinibMelanoma: oncogenic drivers and the immune systemAdoptive T-cell transfer therapy and oncogene-targeted therapy for melanoma: the search for synergyUnderstanding the Impact of ErbB Activating Events and Signal Transduction on Antigen Processing and Presentation: MHC Expression as a Model.BRAF activates and physically interacts with PAK to regulate cell motilitySystems Analysis of Adaptive Responses to MAP Kinase Pathway Blockade in BRAF Mutant Melanoma.Development of [11C]vemurafenib employing a carbon-11 carbonylative Stille coupling and preliminary evaluation in mice bearing melanoma tumor xenograftsA potential role for immunotherapy in thyroid cancer by enhancing NY-ESO-1 cancer antigen expressionCombined BRAF(V600E)- and SRC-inhibition induces apoptosis, evokes an immune response and reduces tumor growth in an immunocompetent orthotopic mouse model of anaplastic thyroid cancer.Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challengesTrial Watch: Peptide-based anticancer vaccines.Effects of BRAF mutations and BRAF inhibition on immune responses to melanomaBRAFV600E Co-opts a Conserved MHC Class I Internalization Pathway to Diminish Antigen Presentation and CD8+ T-cell Recognition of MelanomaMelanoma Expressed-CD70 Is Regulated by RhoA and MAPK Pathways without Affecting Vemurafenib Treatment Activity.Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.NLRC5/MHC class I transactivator is a target for immune evasion in cancer.Tumor-Infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid CancerCombining targeted therapy with immunotherapy. Can 1+1 equal more than 2?Antitumor Activity of BRAF Inhibitor and IFNα Combination in BRAF-Mutant MelanomaThe next generation of orthotopic thyroid cancer models: immunocompetent orthotopic mouse models of BRAF V600E-positive papillary and anaplastic thyroid carcinomaImpact of MAPK Pathway Activation in BRAF(V600) Melanoma on T Cell and Dendritic Cell Function.Immune consequences of kinase inhibitors in development, undergoing clinical trials and in current use in melanoma treatment.Pembrolizumab joins the anti-PD-1 armamentarium in the treatment of melanoma.Synergy of molecular targeted approaches and immunotherapy in melanoma: preclinical basis and clinical perspectives.Crosstalk signaling in targeted melanoma therapy.Cancer-induced heterogeneous immunosuppressive tumor microenvironments and their personalized modulation.Novel melanoma therapy.Combination strategies to enhance the potency of monocyte-derived dendritic cell-based cancer vaccines.Regulatory properties of statins and rho gtpases prenylation inhibitiors to stimulate melanoma immunogenicity and promote anti-melanoma immune response.Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma.Immunomodulating property of MAPK inhibitors: from translational knowledge to clinical implementation.Oncogenic growth factor signaling mediating tumor escape from cellular immunity.Role of interferon in melanoma: old hopes and new perspectives.Long-lasting tumor response on short-time administration of vemurafenib-A case report.Adoptive T cell therapy: An overview of obstacles and opportunities.A Multikinase and DNA-PK Inhibitor Combination Immunomodulates Melanomas, Suppresses Tumor Progression, and Enhances Immunotherapies.Oncogene-Expressing Senescent Melanocytes Up-Regulate MHC Class II, a Candidate Melanoma Suppressor Function.Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma.Biological insights into BRAF(V600) mutations in melanoma patient: Not mere therapeutic targetsEGFR-mediated tumor immunoescape: The imbalance between phosphorylated STAT1 and phosphorylated STAT3.
P2860
Q26744335-5ED0CAC5-3136-4B97-BC6E-30C6B92F1502Q26775598-51D52CC0-91F9-474D-95F2-CD26B2AB0070Q26822793-A4F872F6-404F-4327-98DC-5392A4D7572FQ27691330-CE3C9CD9-02CB-4D1F-9109-065B6E94CCB2Q28248127-BD380DD5-B3B2-4D91-8E41-527829368D46Q28548486-61A8E227-D036-4885-BE48-AF08D750B0A2Q33888789-94465690-F98E-4DF2-9FF2-495B66381A40Q33931434-6399BADE-356E-4FCF-80A8-42F4723F5960Q34100838-E810B28F-B483-4790-828C-D5086E645EF5Q34185078-DECDE4FA-457E-4E6A-8CD7-D3860E0CB005Q34483345-13B2DABD-CAC2-48FB-8DBC-3153E70B4A3FQ34646279-7DCD7562-DBC4-4D15-9945-2B76DD71119BQ35688821-5DD64847-AEAE-4D5E-9E6B-5617144E2E60Q35909427-5860EC39-8A87-4B31-804B-7911F4F3BFFAQ36612452-ABDCF1E6-D6DA-4381-AAF9-F87CD0D2F88AQ36957315-C0BC3EC5-5F5E-4B1C-8EB2-B567EC4BF928Q37057942-66F518FE-C5EC-44B2-8212-5242DB8E945DQ37066925-4AED0F3B-EA45-496A-BA39-23EB3BEA3210Q37102302-E7BF5FD9-6583-496B-A65F-66A9C053E9CCQ37712700-67BEE67B-C331-41EC-88AF-A40E829A0644Q38160220-AEEE37D0-8836-47AE-9C87-1A5253C9F4BDQ38221107-786DD4AF-C953-4001-BFE6-7DD54718BAF6Q38312053-89325C5E-35AC-4DC1-B318-472CC991A10EQ38553161-EBE5D65F-EAE6-498F-8FFC-47668F0D7F71Q38757522-05FDD9E9-22B9-4C97-90AC-235CA2A8F977Q38892904-8EF295F7-3759-4CE7-A382-5216B88F06EEQ38923489-0D59DBAA-85BB-410D-9A7D-E783AF2BC70EQ38948897-FEFA85AF-67B0-4294-89B3-26D538D47C8FQ38951511-A39554A9-88DA-4427-BFF4-15FB19F21A14Q38998443-BDC5CD88-B8EB-4882-B6B6-0E09A405FB81Q39043132-585CDABA-B1C1-4C1A-BD60-FA2E3EAC21D6Q39139069-FC63B565-EF85-4B09-B92F-AD77AC583AAAQ39168894-DD31B26A-4D0C-42D8-A74A-8B66B39A1BDDQ39321751-4648C4B9-EDED-4739-98D9-1DA849A535E2Q39329596-C4D94280-9DF8-43EA-BDE3-92586E6DC279Q40095340-94E26A9F-6D7E-4328-BC03-1E150FAF6E8EQ40159365-32840A53-996B-434F-9831-94AC47186B97Q40987506-ADC116AE-3D12-4218-9E95-035D9EB87108Q41845397-7A9EA4A1-C4DF-4918-84A8-25C266FC9DBCQ41913268-77A296A3-5E5A-469F-93F7-C21F9FB03949
P2860
Vemurafenib enhances MHC induction in BRAF(V600E) homozygous melanoma cells
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Vemurafenib enhances MHC induction in BRAF(V600E) homozygous melanoma cells
@ast
Vemurafenib enhances MHC induction in BRAF(V600E) homozygous melanoma cells
@en
type
label
Vemurafenib enhances MHC induction in BRAF(V600E) homozygous melanoma cells
@ast
Vemurafenib enhances MHC induction in BRAF(V600E) homozygous melanoma cells
@en
prefLabel
Vemurafenib enhances MHC induction in BRAF(V600E) homozygous melanoma cells
@ast
Vemurafenib enhances MHC induction in BRAF(V600E) homozygous melanoma cells
@en
P2093
P2860
P356
P1433
P1476
Vemurafenib enhances MHC induction in BRAF(V600E) homozygous melanoma cells
@en
P2093
Bishu Sapkota
Brian P Pollack
Charles E Hill
P2860
P304
P356
10.4161/ONCI.22890
P577
2013-01-01T00:00:00Z